US 12,109,020 B2
System and method for non-invasive monitoring of advanced glycation end-products (AGE)
Rodolphe Katra, Blaine, MN (US)
Assigned to Medtronic Monitoring, Inc., San Jose, CA (US)
Filed by Medtronic Monitoring, Inc., San Jose, CA (US)
Filed on Jul. 1, 2021, as Appl. No. 17/365,719.
Application 17/365,719 is a division of application No. 15/866,160, filed on Jan. 9, 2018, granted, now 11,051,727.
Prior Publication US 2021/0321912 A1, Oct. 21, 2021
Int. Cl. A61B 5/1455 (2006.01); A61B 5/00 (2006.01); A61B 5/145 (2006.01); G01N 27/327 (2006.01)
CPC A61B 5/1455 (2013.01) [A61B 5/0071 (2013.01); A61B 5/14532 (2013.01); G01N 27/3271 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A system comprising:
a medical device comprising:
a light emitter configured to provide incident light to tissue of a patient at one excitation wavelength; at least one photodetector configured to monitor an emission response to the incident light at a first emission wavelength and at a second emission wavelength; and
one or more processors configured to:
determine a concentration of an advanced glycation end-product (AGE) based on a ratio of the emission response at the first emission wavelength to the emission response at the second emission wavelength, wherein the emission response at the first emission wavelength is associated with a maximum of the emission response and the emission response at the second emission wavelength is associated with a minimum of the emission response;
compare the determined concentration to a threshold; and
generate an alert based on the comparison.